After the price reduction, the medicine is now available at Rs 3,250 per pre-filled syringe plus taxes
New Delhi, June 13, 2015
The move to reduce its cost of therapy is in line with Roche’s commitment to treat patients with Hepatitis C, which continues to be a substantial disease burden in the northern states of India…, it added.
Exxura is available as a pre-filled syringe version to the patients, which offers dosing accuracy and convenience, the company said.
Commenting on the development, Director – Market Access for Roche India V Simpson Emmanuel said: “Roche is committed to working with the government and other stakeholders to control Hepatitis C infection…”
The company, quoting WHO, said 12 million people are chronically infected with Hepatitis C infection in India. PTI